Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and ...

Eli Lilly's next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should help solidify the ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...

At WIRED's Big Interview event, Eli Lilly and Company's Executive Vice President and Chief Information and Digital Officer, ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...